European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency

Keen, Richard; Iolascon, Giovanni; Kruse, H.‐P.; Varbanov, Alex; Mann, Birgit; Gold, Deborah T.

doi:10.1185/030079906x154079

Cited by 25 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another US preference study found that, when informed about the differences in fracture efficacy between weekly and monthly therapy, patients overwhelmingly preferred weekly therapy (82% vs. 18%) 64 . A recent multi-national preference study reached the same conclusion; 82% of female respondents preferred weekly to monthly therapy and fracture efficacy was the principal driver of their preference 65 .…”

Section: Discussionmentioning

confidence: 88%

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Weiß

Henderson

McHorney

et al. 2007

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Weiß

Henderson

McHorney

et al. 2007

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…Preference among osteoporosis treatment options is mainly influenced by fracture efficacy, tolerability, and convenience of the dosing regimen [21, 22]. As has been demonstrated with once weekly and once monthly dosing forms of risedronate, risedronate 75 mg 2CDM has an efficacy and safety profile similar to the 5 mg daily regimen over 2 years [10, 18].…”

Section: Discussionmentioning

confidence: 99%

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

McClung

Benhamou²,

Man³

et al. 2012

Calcif Tissue Int

View full text Add to dashboard Cite

This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. Postmenopausal women with osteoporosis were randomly assigned to double-blind treatment with risedronate 75 mg on 2 consecutive days each month (2CDM) or 5 mg daily. The primary end point was the percentage change from baseline in lumbar spine bone mineral density (BMD) at 12 months. Secondary end points included the change in BMD of the lumbar spine and proximal femur and in bone turnover markers as well as the number of subjects with at least one new vertebral fracture over 24 months. Among 1,229 patients who were randomized and received at least one dose of risedronate, lumbar spine BMD was increased in both treatment groups: mean percentage change from baseline was 4.2 ± 0.19 and 4.3 ± 0.19 % in the 75 mg 2CDM and 5 mg daily groups, respectively, at month 24. The treatment difference was 0.17 (95 % confidence interval −0.35 to 0.68). There were no statistically significant differences between treatment groups on any secondary efficacy parameters. Both treatment regimens were well tolerated. Risedronate 75 mg 2CDM was noninferior in BMD efficacy and did not show a difference in tolerability compared to 5 mg daily after 24 months of treatment in women with postmenopausal osteoporosis. This monthly regimen may provide a more convenient dosing schedule to some patients with postmenopausal osteoporosis.

show abstract

“…However, adherence to treatment decreases with older age because of forgetfulness, inability to handle the packaging, multimorbidity and multimedication [27, 32]. Besides adherence to therapy, compliance with the prescribed dosage is also often inadequate: older patients often take the medication less frequently than prescribed [24, 27] It is reasonable to conclude that a more convenient formulation and less frequent administration would lead to improved compliance in the elderly [8, 33]. …”

Section: Discussionmentioning

confidence: 99%

Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial

et al. 2009

View full text Add to dashboard Cite

Preference for a drug formulation is important in adherence to long-term medication for chronic illnesses such as osteoporosis. We investigated the preference for and acceptability of chewable tablet containing calcium and vitamin D (Calci Chew D3, Nycomed) compared to that of a sachet containing calcium and vitamin D3 (Cad, Will-Pharma). This open, randomised, cross-over trial was set up to compare the preference and acceptability of two calcium plus vitamin D3 formulations (both with 500 mg calcium and 400/440 IU vitamin D3), given twice a day in patients with osteoporosis. Preference and acceptability were assessed by means of questionnaires. Preference was determined by asking the question, which treatment the patient preferred, and acceptability was measured by scoring five variables, using rating scales. Of the 102 patients indicating a preference for a trial medication, 67% preferred the chewable tablet, 19% the sachet with calcium and vitamin D3, and 15% stated no preference. The significant preference for Calci Chew D3 (p < 0.0001) was associated with higher scores for all five acceptability variables. The two formulations were tolerated equally well. A significant greater number of patients considered the chewable tablet as preferable and acceptable to the sachet, containing calcium and vitamin D3. Trial registration: Current Controlled Trials ISRCTN18822358.

show abstract

European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency

Cited by 25 publications

References 15 publications

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

Patient preference and acceptability of calcium plus vitamin D3 supplementation: a randomised, open, cross-over trial

Contact Info

Product

Resources

About